Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

Mes dernières consult.
Most popular
Delayed Quote. Delayed  - 01/18 06:57:40 pm
58.8 USD   -0.32%
12:20p BIOCENTURY - MA : NanoString, Orchard
01/11 ABBOTT LABORATO : ex-dividend day
01/05 ABBOTT LABORATO : Revolutionary continuous glucose monitoring system..
News SummaryMost relevantAll newsSector newsTweets

Abbott Laboratories : Abbott and AbbVie Announce Investor Calls

share with twitter share with LinkedIn share with facebook
share via e-mail
01/14/2013 | 04:10pm CET

Abbott Park, Illinois and North Chicago - Abbott (NYSE: ABT) will announce its fourth-quarter and full-year 2012 financial results on Wednesday, Jan. 23, 2013, before the market opens.

Abbott's quarterly and annual results will include contributions from the company's former research-based pharmaceutical business, which became AbbVie on Jan. 1, 2013. While these results will be captured in a single press release, both companies will host separate conference calls to discuss their respective business results and 2013 outlooks.

Abbott will host a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) on Jan. 23, 2013. It will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available after 11 a.m. Central time.

On Wednesday, Jan. 30, 2013, AbbVie will host a live webcast at 8 a.m. Central time (9 a.m. Eastern) accessible through AbbVie's Investor Relations website at www.abbvieinvestor.com. An archived edition of the call will be available after 11 a.m. Central time.

About Abbott

Abbott (NYSE: ABT) is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 70,000 people.

About AbbVie

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. With its 125-year history, the company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. In 2013, AbbVie employs approximately 21,000 people worldwide and markets medicines in more than 170 countries.www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

Abbott Contacts:
Scott Stoffel

(847) 936-9502
Brian Yoor

(847) 937-6343
AbbVie Contacts:
Adelle Infante

(847) 938-8745
Larry Peepo

(847) 935-6722
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
12:20p BIOCENTURY - MANAGEMENT TRACKS : NanoString, Orchard
01/12 ABBOTT LABORATORIES : Miles White`s Bold Moves Made Abbott Laboratories A Global..
01/11 ABBOTT LABORATORIES : ' Trademark Application for "FEED THE 485" Filed
01/11 ABBOTT LABORATORIES : Trademark Application for "FEED THE 485 INITIATIVE" Filed ..
01/11 ABBOTT LABORATORIES : Patent Application Titled "Infant Formula Comprising Human..
01/11 ABBOTT LABORATORIES : (ABT) Position Lessened by Shelter Mutual Insurance Co
01/11 ABBOTT LABORATORIES : ex-dividend day
01/08 ABBOTT LABORATORIES : ABT) Stock Price Declined, Kdi Capital Partners Decreased ..
01/06 ABBOTT LABORATORIES : Medicare patients with diabetes gain coverage for Abbott`s..
01/05 ABBOTT LABORATORIES : Revolutionary continuous glucose monitoring system freesty..
More news
News from SeekingAlpha
01/15 My Dividend Growth Portfolio - Q4 2017 Summary
01/13 THE PASSIVE DGI CORE PORTFOLIO : 2017 End-Of-Year Review
01/12 YOUR DAILY PHARMA SCOOP : AbbVie Highlights Pipeline, Novavax Surges, Lipocine F..
01/12 DALE'S 2017 PORTFOLIO REVIEW : Let The Good Times Roll
01/11 YOUR DAILY PHARMA SCOOP : Roche Highlights Pipeline, GenSight Gets Nod To Start ..
Financials ($)
Sales 2017 27 195 M
EBIT 2017 6 011 M
Net income 2017 2 227 M
Debt 2017 17 359 M
Yield 2017 1,82%
P/E ratio 2017 50,85
P/E ratio 2018 38,99
EV / Sales 2017 4,41x
EV / Sales 2018 3,89x
Capitalization 103 B
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 63,6 $
Spread / Average Target 7,8%
EPS Revisions
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Executive VP-Finance
Randel W. Woodgrift VP-Abbott Medical Devices Cardiovascular
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON5.11%394 542
NOVARTIS1.02%227 089
PFIZER1.05%218 162
ROCHE HOLDING LTD.-5.33%211 361
MERCK AND COMPANY10.24%169 287